Anti-cancer drugsHumansMaleProstatic NeoplasmsCastration-ResistantProspective Studies
Real-world treatment patterns and survival outcomes in patients with metastatic castration-resistant prostate cancer in France: lessons from the prospective OPALE study.
Josephine Papet, Laetitia Augusto-Pelegrin, François Christy, Justine Lequesne, Frederic Di Fiore, Florence Joly, Christian Pfister
Published: 202510.1097/CAD.0000000000001756
Abstract
In metastatic castration-resistant prostate cancer (mCRPC), several treatments are available, including androgen-receptor pathway inhibitors (ARPis) and chemotherapy (CT). There is a lack of real-world prospective data on treatment sequences and surv…
Preview only. Read the full abstract at the source